Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

Also called NCT02625948

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02625948
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
Not reported
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02625948. Randomized; quadruple masking; primary purpose treatment. Start 2015-09 (registry gives no type); primary completion 2018-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign
Acronym
TRAIGE
Condition
Intracerebral Hemorrhage
Condition
Stroke
Intervention (Drug)
Tranexamic Acid
Lead sponsor
Ministry of Science and Technology of the People´s Republic of China (class: other government)
Collaborator
Beijing Municipal Science & Technology Commission (class: other)

Record details

Record id
cardio:ct-nct02625948
Content hash
036e3a173fe57759b6b222d9e5863b5e65188eec2f37c7c2e308029a97c39068